Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Inhaled alprazolam race: can it beat IV sedatives?

NCT ID NCT07020988

First seen Jan 21, 2026 · Last updated Jun 23, 2026 · Updated 22 times

Summary

This completed phase 1 study tested how quickly an inhaled form of alprazolam (Staccato) affects brain activity compared to intravenous midazolam and nasal diazepam. Fifty-five healthy adults received single doses of each drug in a crossover design. Researchers used EEG brain wave monitoring to measure the time to onset of action. The goal is to see if this inhaled approach could provide a fast, needle-free option for conditions like seizures.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Up0127 1001

    Glendale, California, 91206, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Staccato alprazolam (inhaled), midazolam (intravenous), diazepam (nasal)

What this could lead to

If successful, this study could show that inhaled alprazolam works as fast as IV sedatives, potentially offering a needle-free option for rapid seizure control.

What could go wrong

This is a very early phase 1 study in only 55 healthy people, not patients. It measures brain wave changes, not real-world seizure stopping. The results may not translate to actual treatment benefits.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.